S&P 500
(1.03%) 5 180.74 points
Dow Jones
(0.46%) 38 852 points
Nasdaq
(1.19%) 16 349 points
Oil
(0.31%) $78.72
Gas
(-1.23%) $2.17
Gold
(-0.03%) $2 330.50
Silver
(0.00%) $27.61
Platinum
(0.80%) $972.65
USD/EUR
(0.05%) $0.929
USD/NOK
(0.15%) $10.84
USD/GBP
(0.05%) $0.796
USD/RUB
(-0.01%) $91.34

Aktualne aktualizacje dla Denali Therapeutics Inc [DNLI]

Giełda: NASDAQ Sektor: Healthcare Branża: Biotechnology
BUY
100.00%
return 12.57%
SELL
62.50%
return 3.52%
Ostatnio aktualizowano6 geg. 2024 @ 23:00

0.00% $ 17.14

KUPNO 118615 min ago

@ $17.66

Wydano: 14 vas. 2024 @ 21:01


Zwrot: -2.94%


Poprzedni sygnał: vas. 13 - 22:45


Poprzedni sygnał: Sprzedaż


Zwrot: 3.03 %

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 23:00):
Profile picture for Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States...

Stats
Dzisiejszy wolumen 597 116
Średni wolumen 1.27M
Kapitalizacja rynkowa 2.44B
EPS $0 ( 2024-02-26 )
Następna data zysków ( $-0.670 ) 2024-05-13
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -16.17
ATR14 $0.0150 (0.09%)
Insider Trading
Date Person Action Amount type
2024-04-15 Sato Vicki L Sell 1 666 Common Stock
2024-04-01 Krognes Steve E. Sell 92 500 Common Stock
2024-03-29 Watts Ryan J. Sell 40 000 Common Stock
2024-03-15 Sato Vicki L Sell 1 666 Common Stock
2024-02-15 Sato Vicki L Sell 1 666 Common Stock
INSIDER POWER
33.15
Last 100 transactions
Buy: 1 164 016 | Sell: 631 404

Wolumen Korelacja

Długi: -0.02 (neutral)
Krótki: 0.74 (moderate)
Signal:(67.734) Neutral

Denali Therapeutics Inc Korelacja

10 Najbardziej pozytywne korelacje
RUBY0.908
ACRS0.907
HAS0.906
TUEM0.902
SBRA0.901
ALHC0.901
SIVBP0.897
MQ0.897
XP0.896
CCSI0.896
10 Najbardziej negatywne korelacje
MBIN-0.912
SCR-0.902
KTCC-0.901
MPWR-0.897
ZIONP-0.891
HUGE-0.889
WIRE-0.889
ITI-0.888
PAE-0.888
ICPT-0.888

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Denali Therapeutics Inc Korelacja - Waluta/Towar

The country flag -0.83
( strong negative )
The country flag -0.76
( moderate negative )
The country flag 0.00
( neutral )
The country flag -0.77
( moderate negative )
The country flag 0.39
( neutral )
The country flag 0.68
( moderate )

Denali Therapeutics Inc Finanse

Annual 2023
Przychody: $330.53M
Zysk brutto: $313.81M (94.94 %)
EPS: $-1.060
FY 2023
Przychody: $330.53M
Zysk brutto: $313.81M (94.94 %)
EPS: $-1.060
FY 2022
Przychody: $108.46M
Zysk brutto: $101.43M (93.52 %)
EPS: $-2.60
FY 2021
Przychody: $48.66M
Zysk brutto: $0.00 (0.00 %)
EPS: $-2.40

Financial Reports:

No articles found.

Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej